Results 171 to 180 of about 121,845 (294)

Associations Between Genetic Risk, Physical Activities, and Distressing Psychotic-like Experiences. [PDF]

open access: yesSchizophr Bull
Ku BS   +8 more
europepmc   +1 more source

Addressing limitations in current measurement practices of trauma assessment in minoritized populations

open access: yesJournal of Traumatic Stress, EarlyView.
Abstract Standardized trauma assessment frameworks often fail to account for the unique experiences and symptom presentations of minoritized populations, including Black, Indigenous, and people of color (BIPOC) and sexual and gender minority (SGM) individuals, leading to methodological inequity.
Krithika Prakash   +4 more
wiley   +1 more source

Epidemiological Signals, Knowledge Gaps, and Practice Considerations From the 2024 Functional Neurological Disorder Society International Meeting: A Conference Report With Narrative Synthesis

open access: yesMedicine Bulletin, EarlyView.
ABSTRACT The 2024 International Conference on Functional Neurological Disorders brought together clinicians, researchers, advocates, and service‐user representatives to discuss recent developments in functional neurological disorder and related functional disorders.
Yadira Velazquez‐Rodriquez   +2 more
wiley   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri   +20 more
wiley   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig   +6 more
wiley   +1 more source

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy